Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 21, 2018

View Archived Issues

GeNeuro monoclonal antibody GNbAC-1 receives U.S. orphan designation for CIDP

BX-795 as a promising new antiviral agent against HSV-1 infection of the eye

Vical starts phase II trial of VL-2397 for treatment of invasive aspergillosis

Allergan exercises third option for DARPin product candidates

Umeclidinium has clinical effects in phase II study in palmar hyperhidrosis

FDA accepts Acorda Therapeutics' NDA for Inbrija

INSERM and collaborators patent antibodies targeting tumor associated macrophages

Xenon Pharmaceuticals initiates clinical testing of antiepileptic drug candidate XEN-901

Novel apoptosis regulator Bcl-2 and/or Bcl-xl inhibitors identified at the University of Michigan

Pivotal phase III PALISADE study of AR-101 meets primary endpoint

University of Hong Kong presents new platinum complexes

Sunshine Lake Pharma identifies new farnesoid X receptor agonists

Max-Planck-Gesellschaft describes novel influenza type b vaccines

Cullinan Oncology, MAB Discovery announce agreement to develop novel antibody therapeutics

Mirikizumab improves quality of life of patients with moderate to severe psoriasis

Imugene reports preclinical in vivo data for arginine modulator

Cedars-Sinai and Emulate pioneer Patient-on-a-Chip program

FDA denies PTC Therapeutics' appeal regarding ataluren NDA, but suggests possible path forward

3D Signatures announces topline results for Telo-HL test for Hodgkin's lymphoma

Genexine to use PharmaJet devices in clinical studies

Soleno Therapeutics completes end-of-phase II meeting for diazoxide choline controlled-release

Celgene licenses technology from Amunix

Alcyone Lifesciences' hydrocephalus business now new company

Safety data presented for tivozanib combined with nivolumab in patients with mRCC

Tetraphase and Everest Medicines sign licensing agreement for eravacycline in China

DNA origami-designed nanorobot delivers thrombin specifically to tumors

Tell us what you think about TRDN

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...